Unknown

Dataset Information

0

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.

ABSTRACT: With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.

SUBMITTER: Fiuzat M 

PROVIDER: S-EPMC9180686 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.

Fiuzat Mona M   Hamo Carine E CE   Butler Javed J   Abraham William T WT   DeFilippis Ersilia M EM   Fonarow Gregg C GC   Lindenfeld Joann J   Mentz Robert J RJ   Psotka Mitchell A MA   Solomon Scott D SD   Teerlink John R JR   Vaduganathan Muthiah M   Vardeny Orly O   McMurray John J V JJV   O'Connor Christopher M CM  

Journal of the American College of Cardiology 20220201 5

With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of backgr  ...[more]

Similar Datasets

Unknown Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week.
| S-EPMC9388228 | biostudies-literature
Unknown Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week.
| S-EPMC9097251 | biostudies-literature
Unknown Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
| S-EPMC8884342 | biostudies-literature
Unknown Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.
| S-EPMC7957366 | biostudies-literature
Unknown Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.
| S-EPMC8168628 | biostudies-literature
Unknown Mitral Valve Dysfunction in Patients With Annular Calcification: JACC Review Topic of the Week.
| S-EPMC10290884 | biostudies-literature
Unknown Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week.
| S-EPMC7454044 | biostudies-literature
Unknown Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
| S-EPMC6354546 | biostudies-literature
Unknown Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review.
| S-EPMC9941752 | biostudies-literature
Unknown Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week.
| S-EPMC7833921 | biostudies-literature